• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review

August 11, 2022 By Jim Hammerand

Better Therapeutics

Better Therapeutics (Nasdaq:BTTX) posted second-quarter quarter results today that beat the consensus forecast on Wall Street as it prepared to submit its first product for FDA review.

Better Therapeutics has not yet generated revenue from the commercialization or sale of any product. The company went public through a special purpose acquisition company merger in October.

The San Francisco-based prescription digital therapeutics developer reported a loss of $9.9 million, or -$0.42 per share, for the three months ended June 30. That’s a 15% larger loss than the same quarter last year, but 3¢ better than analysts’ expectations of a $0.45 loss.

Better Therapeutics said last month it would seek FDA De Novo classification in Q3 for its first product, the BT-001 therapy for adults with uncontrolled type 2 diabetes.

New President and CEO Frank Karbe said today that the company is on track to submit BT-001 this quarter.

A portrait of Better Therapeutics CEO and President Frank Karbe
Better Therapeutics CEO and President Frank Karbe [Photo courtesy of Better Therapeutics]

“Better Therapeutics is poised to enter the next phase of its growth as a commercial company, with the recent completion of the BT-001 pivotal trial and, if authorized by the FDA, the potential launch of our first-in-class prescription digital therapeutic for the treatment of type 2 diabetes next year,” Karbe said in a news release. “The pivotal trial of BT-001 met its primary and secondary endpoints and demonstrated a reassuring safety profile in a diverse and difficult to treat patient population, resulting in significant A1c reductions when compared with the current standard of care.”

R&D expenses for the quarter decreased to $4.2 million from $5 million in Q2 2021. Clinical study costs decreased due to the BT-001 pivotal trial wind-down, but personnel and consulting costs increased to prepare the FDA submission and expand clinical research and software development capabilities, the company said.

Investors reacted by sending BTTX shares up less than 2% to $1.81 at mid-day.

Filed Under: Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Technology, Uncategorized Tagged With: Better Therapeutics, Diabetes

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

About Jim Hammerand

Jim Hammerand is the managing editor of Medical Design & Outsourcing. He has more than 15 years of professional journalism experience spanning newspapers, magazines, websites and broadcast news. For nearly a decade, he reported and edited business news for American City Business Journals as a reporter and digital editor at the Minneapolis/St. Paul Business Journal and then managing editor of the Puget Sound Business Journal in Seattle. He holds a bachelor’s degree in journalism from the University of Minnesota. He is based near Seattle in Edmonds, Washington, where he and his family live. Connect with him on LinkedIn or by email at jimhammerand@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS